ArticleMolecules (Basel, Switzerland)2009
Synthesis and pharmacological screening of several aroyl and heteroaroyl selenylacetic acid derivatives as cytotoxic and antiproliferative agents.
Article in Molecules (Basel, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Selenium-Containing 1,4-Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple-Negative Breast Cancer Cells.Drug development research · 2026Article
- New Se-Compounds With Antileishmanial, Antitumor, and Carbonic Anhydrase Inhibitory Properties.Archiv der Pharmazie · 2025Article
- First Generation of Antioxidant Precursors for Bioisosteric Se-NSAIDs: Design, Synthesis, and In Vitro and In Vivo Anticancer Evaluation.Antioxidants (Basel, Switzerland) · 2023Article
- Exploring Novel Drug Combinations: The Therapeutic Potential of Selanyl Derivatives for Leishmania Treatment.Molecules (Basel, Switzerland) · 2023Article
- Seleno-Analogs of Scaffolds Resembling Natural Products a Novel Warhead toward Dual Compounds.Antioxidants (Basel, Switzerland) · 2023Article
- Design, Synthesis and Anticancer Activity of a New Series ofMolecules (Basel, Switzerland) · 2021Article
- Vilsmeier reagent, NaHSe and diclofenac acid chloride: one-pot synthesis of a novel selenoindolinone with potent anticancer activity.RSC advances · 2020Article
- Selenocompounds as Novel Antibacterial Agents and Bacterial Efflux Pump Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- Selenides and Diselenides: A Review of Their Anticancer and Chemopreventive Activity.Molecules (Basel, Switzerland) · 2018Review
- Zerumbone-Loaded Nanostructured Lipid Carrier Induces Apoptosis of Canine Mammary Adenocarcinoma Cells.BioMed research international · 2018Article
- Atom Efficient Preparation of Zinc Selenates for the Synthesis of Selenol Esters under "On Water" Conditions.Molecules (Basel, Switzerland) · 2017Article
- Synthesis and in vitro antitumor activity of (1Chemistry Central journal · 2017Article
- Novel library of selenocompounds as kinase modulators.Molecules (Basel, Switzerland) · 2011Article
- Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates.Parasitology research · 2011Article
- Antioxidant-prooxidant properties of a new organoselenium compound library.Molecules (Basel, Switzerland) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synthesis and cytotoxic activity of a series of twenty six aroyl and heteroaroyl selenylacetic acid derivatives of general formula Ar-CO-Se-CH(2)-COOH or Heterar-CO-Se-CH(2)-COOH are reported. The synthesis was carried out by reaction of acyl chlorides with sodium hydrogen selenide, prepared in situ, and this led to the formation of sodium aroylselenides that subsequently reacted with alpha-bromoacetic acid to produce the corresponding selenylacetic acid derivatives. All of the compounds were tested against a prostate cancer cell line (PC-3) and some of the more active compounds were assessed against a panel of four human cancer cell lines (CCRF-CEM, HTB-54, HT-29, MCF-7) and one mammary gland-derived non-malignant cell line (184B5). Some of the compounds exhibited remarkable cytotoxic and antiproliferative activities against MCF-7 and PC-3 that were higher than those of the reference compounds doxorubicin and etoposide, respectively. For example, in MCF-7 when Ar = phenyl, 3,5-dimethoxyphenyl or benzyl the TGI values were 3.69, 4.18 and 6.19 microM. On the other hand, in PC-3 these compounds showed values of 6.8, 4.0 and 2.9 microM. Furthermore, benzoylselenylacetic acid did not provoke apoptosis nor did it perturb the cell cycle in MCF-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.